Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: Meta-analysis of six initial trials and five long-term extensions

Modern Rheumatology

Volumn 20, Issue 3, 2010, Pages 222-232

  Nishimoto, Norihiro ^a   Ito, Kyoko ^b   Takagi, Nobuhiro ^b  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Clinical trial; Interleukin 6; Meta analysis; Rheumatoid arthritis; Tocilizumab

Indexed keywords

ANTIRHEUMATIC AGENT; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 6 RECEPTOR ALPHA; INTERLEUKIN-6 RECEPTOR ALPHA; MONOCLONAL ANTIBODY; TOCILIZUMAB;

ARTICLE; ASIAN; DRUG ANTAGONISM; HUMAN; IMMUNOLOGY; META ANALYSIS; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ASIAN CONTINENTAL ANCESTRY GROUP; HUMANS; RECEPTORS, INTERLEUKIN-6; TREATMENT OUTCOME;

EID: 77956646068     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-010-0279-5     Document Type: Article

References (32)

1. Harris ED Jr. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med. 1990;322(18):1277-89.
2. Cush JJ, Lipsky PE. Phenotypic analysis of synovial tissue and peripheral blood lymphocytes isolated from patients with rheumatoid arthritis. Arthritis Rheum. 1988;31(10):1230-8.
3. Nishimoto N, Kishimoto T. Il-6 from bench to bedside. Nat Clin Pract Rheumatol. 2006;2(11):619-26.
4. Kudo O, Sabokbar A, Pocock A, Itonaga I, Fujikawa Y, Athanasou NA. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone. 2003;32(1):1-7. (Pubitemid 36173806)
5. Straub RH, Muller-Ladner U, Lichtinger T, Scholmerich J, Menninger H, Lang B. Decrease of interleukin 6 during the first 12 months is a prognostic marker for clinical outcome during 36 months treatment with disease-modifying anti-rheumatic drugs. Br J Rheumatol. 1997;36(12):1298-303.
6. Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T, et al. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res. 1993;53(4):851-6. (Pubitemid 23077873)
7. Nishimoto N, Yoshizaki K, Maeda K, Kuritani T, Deguchi H, Sato B, et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol. 2003;30(7):1426-35. (Pubitemid 36835435)
8. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004; 50(6):1761-9. (Pubitemid 38725087)
9. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66(9):1162-7. (Pubitemid 47309731)
10. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19(1): 12-9.
11. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an anti-interleukin- 6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis. 2009;68(10):1580-4.
12. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-24. (Pubitemid 18091653)
13. Fransen J, Creemers MC, Van Riel PL. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford). 2004;43(10):1252-5. (Pubitemid 39359299)
14. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363(9410):675-81. (Pubitemid 38296553)
15. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343(22):1594-602.
16. Fujiwara H, Nishimoto N, Hamano Y, Asanuma N, Miki S, Kasayama S, et al. Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases. Mod Rheumatol. 2009;19(1):64-8.
17. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345(15):1098-104.
18. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003;48(8):2122-7.
19. Gutierrez-Macias A, Lizarralde-Palacios E, Martinez-Odriozola P, Miguel-de la Villa F. Tuberculous peritonitis in a patient with rheumatoid arthritis treated with adalimumab. Clin Rheumatol. 2007;26(3):452-3.
20. Harris J, Hope JC, Keane J. Tumor necrosis factor blockers influence macrophage responses to Mycobacterium tuberculosis. J Infect Dis. 2008;198(12):1842-50.
21. Yamada T, Nakajima A, Inoue E, Tanaka E, Hara M, Tomatsu T, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan. Ann Rheum Dis. 2006;65(12):1661-3. (Pubitemid 44799684)
22. Myasoedova E, Talley NJ, Crowson CS, Gabriel SE. Increased risk of gastrointestinal events in rheumatoid arthritis (abstract). Ann Rheum Dis. 2009;68[Suppl 3]:415.
23. Yamanaka H, Nishimoto N, Inoue E, Hara M, Tomatsu T, Kamatani N. Incidence of malignancies in Japanese rheumatoid arthritis patients treated with tocilizumab in comparison to those in an observational cohort of Japanese patients and a Japanese population database (abstract). Ann Rheum Dis. 2007;66[Suppl 2]:122.
24. Suwa T, Hogg JC, English D, Van Eeden SF. Interleukin-6 induces demargination of intravascular neutrophils and shortens their transit in marrow. Am J Physiol Heart Circ Physiol. 2000;279(6):H2954-60. (Pubitemid 32005886)
25. Newland AC, Macey MG, Veys PA. Cellular changes during the infusion of high dose intravenous immunoglobulin. Blut. 1989;59(1):82-7. (Pubitemid 19188435)
26. Katz A, Chebath J, Friedman J, Revel M. Increased sensitivity of IL-6-deficient mice to carbon tetrachloride hepatotoxicity and protection with an IL-6 receptor-IL-6 chimera. Cytokines Cell Mol Ther. 1998;4(4):221-7. (Pubitemid 28543005)
27. Singh G, Mannalithara A, Mithal A, Triadafilopoulos G. Acute myocardial infarction in rheumatoid arthritis: has better control of inflammation made a difference (abstract)? Arthritis Rheum. 2007;56[Suppl 9]:810.
28. Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, et al. Double-blind, randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54(9):2817-29. (Pubitemid 44497760)
29. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987-97. (Pubitemid 351392039)
30. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics: results from a 24-week multicentre randomised placebo controlled trial. Ann Rheum Dis. 2008;67(11):1516-23.
31. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER Study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus Methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous Methotrexate treatment. Arthritis Rheum. 2006;54(1):26-37. (Pubitemid 43122183)
32. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008; 58(10):2968-80.